Skip to main content
Fig. 3 | BMC Rheumatology

Fig. 3

From: Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

Fig. 3

Kaplan–Meier curves comparing time to an unfavorable cancer outcome. Time to an unfavorable cancer outcome (event) based on a incidence of a flare or irAE (n = 27, 24 events) versus those without (n = 18, 13 events), b occurrence of a flare of irAE that required oral or intravenous (n = 21, 19 events) steroids versus those without an event requiring systemic steroids (n = 24, 18 events), c ICI being held due to a flare or irAE (n = 16, 14 events) versus continued (n = 11, 10 events), d treatment for the rheumatologic disease during ICI (n = 22, 19 events) versus no treatment (n = 23, 18 events), and e rheumatoid arthritis (n = 22, 19 events) versus other rheumatologic disease (n = 23, 18 events). None of comparisons showed a statistically significant difference between levels of each stratification factor in time to unfavorable cancer outcomes

Back to article page